ISONIAZID

Course overview

Isoniazid (INH) is U.S. FDA-approved in combination with other antituberculars to treat active tuberculosis (TB) in all patients, and as monotherapy to treat latent TB infection (LTBI) in all patients. This continuing education module is designed to give the reader/learner an increased understanding of isoniazid. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.